Log In
BCIQ
Print this Print this
 

CM-101

  Manage Alerts
Collapse Summary General Information
Company ChemomAb Ltd.
DescriptionMAb targeting and blocking chemokine CC motif ligand 24 (CCL24; MPIF2; Eotaxin-2)
Molecular Target Chemokine CC motif ligand 24 (CCL24) (MPIF2) (Eotaxin-2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat immune-mediated disorders
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today